ZNTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zentalis Pharmaceuticals Inc (ZNTL) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is weak, with significant revenue and profitability challenges, and the technical indicators do not suggest a strong entry point. Additionally, there are no positive catalysts or strong trading signals to support a buy decision at this time.
The stock's MACD is negative and expanding, indicating a bearish trend. RSI is neutral at 40.594, and moving averages are converging, showing no clear trend. The stock is trading near its S2 support level of 2.34, but there is no indication of a reversal or strong buying opportunity.
NULL identified. No significant insider or hedge fund activity, and no recent congress trading data.
The company reported a FY 2025 GAAP EPS of -$1.91, highlighting profitability challenges. Revenue dropped to $0 in Q4 2025, down 100% YoY, and net income decreased by 25.82% YoY. The company faces increasing competition in the pharmaceutical sector, requiring enhanced R&D and marketing efforts.
In 2025/Q4, revenue dropped to $0 (-100% YoY), net income dropped to -$35.216 million (-25.82% YoY), EPS dropped to -$0.49 (-26.87% YoY), and gross margin dropped to 0 (-100% YoY). The company had $245.9 million in cash and marketable securities as of December 31, 2025.
No recent updates on analyst ratings or price target changes were provided.
